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Abstract
Background: Acute respiratory infections (ARI) are among the leading causes
of hospitalization in children ≤5 years old. Rapid diagnostics of viral pathogens
is essential to avoid unnecessary antibiotic treatment, thereby slowing down
antibiotic-resistance. We evaluated the diagnostic performance of the Luminex
xTAG Respiratory Viral Panel FAST v2 against viral specific PCR as reference
assays for ARI in Vietnam.
Methods: Four hundred and forty two nose and throat swabs were collected in
viral transport medium, and were tested with Luminex xTAG Respiratory Viral
Panel FAST v2. Multiplex RT-PCR and single RT-PCR were used as
references.   
Results: Overall, viral pathogens were detected in a total count of 270/294
(91.8%, 95% CI 88.1-94.7) by the Luminex among reference assays, whilst
112/6336 (1.8%, 95% CI, 1.4-2.1) of pathogens were detected by the Luminex,
but not by reference assays. Frequency of pathogens detected by Luminex and
reference assays was 379 and 292, respectively. The diagnostic yield was
66.7% (295/442, 95%CI 62.1-71.1%) for the Luminex assay and 54.1%
(239/442, 95% CI, 49.3-58.8%) for reference assays. The Luminex kit had
higher yields for all viruses except influenza B virus, respiratory syncytial virus,
and human bocavirus. High agreements between both methods [mean (range):
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 and human bocavirus. High agreements between both methods [mean (range):
0.91 (0.83-1.00)] were found for 10/15 viral agents.
Conclusions: The Luminex assay is a high throughput multiplex platform for
rapid detection of common viral pathogens causing ARI. Although the current
high cost may prevent Luminex assays from being widely used, especially in
limited resource settings where ARI are felt most, its introduction in clinical
diagnostics may help reduce unnecessary use of antibiotic prescription.
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Introduction
Acute respiratory infections (ARI) are the leading cause of 
morbidity and mortality in infants and children worldwide, 
especially in Southeast Asia (including Vietnam) and Africa1,2. 
In Vietnam, there is a high burden of ARI in children in the first 
year of life, who are more likely to be admitted to intensive  care 
and have a longer hospital stay than children with other infectious 
diagnoses3.
Viruses are the most common causes of ARI4–8. Rapid identi-
fication of causative agents is therefore of clinical and public 
health significance, and may reduce the widespread inappropriate 
use of antibiotics.
The advances in molecular diagnostics have provided powerful 
means for detection of viruses in terms of sensitivity, specificity 
and turnaround time5,9–12. The introduction of multiplex PCR for 
detection of a panel of respiratory pathogens enables faster results, 
higher throughput and lower cost13,14.
The Luminex xTAG Respiratory Viral Panel (RVP) FAST v2 
assay (Luminex Molecular Diagnostics, Toronto, ON, Canada) is a 
qualitative multiplex molecular diagnostic assay for simultaneous 
detection of 19 viral types and subtypes within two hours in a 
single reaction. It was approved in September 2012 by the US 
Food and Drug Administration (FDA). Previous reports have 
shown that the sensitivity of Luminex RVP FAST system varied 
between settings, while the specificity was consistently high15–19. 
Here, we aimed to evaluate the diagnostic performance of the 
Luminex xTAG RVP FAST v2 (hereafter called Luminex) against 
a combination of a number of published reference assays on 
clinical specimens collected from patients with ARI from four 
provincial hospitals in Vietnam.
Methods
Study samples and study procedure
This is a retrospective study. Respiratory samples were derived 
from the Vietnam initiative on Zoonotic infections (VIZIONS) 
study20. This study was approved by the local ethical committee 
and the Oxford Tropical Research Ethics Committee (OxTREC 
Approval No. 15-12). The Institutional Review Boards of the 
hospital sites (Daklak, Dong Thap, Hue, and Khanh Hoa) submitted 
the official document approvals to the Hospital for Tropical 
Diseases (HTD) local ethics committee. The HTD then gave ethical 
approval (approval no. CS/ND/13/28). Written informed consent 
was obtained from all patients or from parents/legal guardians if 
the patient was a child prior to enrolment into the study. In and 
outpatients with a clinical diagnosis of ARI were recruited from 
four provincial hospitals (in Cao Lanh, Dong Thap; Buon Me 
Thuot, Dak Lak; Nha Trang, Khanh Hoa; and Hue). The study 
inclusion criteria consisted of fever or history of fever of less than 
7 days and respiratory symptoms as the chief complaint. On the 
day of enrollment, nose and throat swabs were collected from 
each patient in separate tubes containing 1ml of sterile viral 
transport medium (VTM). Samples were stored at -80°C and trans-
ported in batches on dry ice to the laboratory of Oxford University 
Clinical Research Unit (OUCRU), Ho Chi Minh City, where the 
nose and throat swabs were pooled for subsequent analysis as per 
study protocols. Four hundred forty-two samples were simultane-
ously tested with the Luminex assay and reference assays.
Nucleic acid extraction
Equal volumes of VTM from nose and throat swabs were pooled 
and subjected to total nucleic acid extraction after addition of 
internal control (EAV - equine arteritis virus for reference 
assays and bacteriophage MS2 for the Luminex assay) using the 
MagNApure 96 platform (Roche Diagnostics, Mannheim, 
Germany), according to the manufacturer’s instructions. Extracted 
nucleic acids were eluted in 50 ul of elution buffer and stored 
at -80°C for further analyses.
Luminex xTAG RVP FAST v2 set
The Luminex assay includes reagents to detect Influenza A virus 
(InfA: generic, H1N1 (1977), H1N1pdm09, H3N2), Influenza 
B virus (InFB), Respiratory Syncytial Virus A & B (RSVA, 
RSVB), enteroviruses including rhinoviruses (ENT/Rhi), human 
parainfluenza viruses 1–4 (PIV1-4), human metapneumovirus 
(hMPV), adenovirus (ADV), human coronavirus NL63 (hCoV 
NL63), hCoV HKU1, hCoV 229E, hCoV OC43, and human 
bocavirus (hBoV). Bacteriophage lambda was included in every 
run to control the amplification and assay performance. The assay 
comprised a PCR amplification and hybridization step, and was 
performed according to the manufacturer’s instructions. Signal 
acquisition presented as MFI (median fluorescence intensity) was 
done on the Luminex MAGPIX instrument. Data was read and 
reported by the TDAS RVP FAST software, version 2.2.
Reference assays
The reference assays included an RT-PCR for RSVA and RSVB21, 
the CDC RT-PCR obtained by protocol transfer agreement with 
the US CDC for universal detection of influenza A virus, influenza 
A virus subtype H1 (1977), influenza A virus subtype H3, and 
InFB [Table 1, CDC Realtime RTPCR (rRTPCR) Protocol for 
Detection and Characterization of Influenza, Revised April 4, 
2006]; and the 4-tube real time multiplex RT-PCR22. Because 
the influenza A viruses, InfB and RVS targets were tested in 
the above specific RT-PCRs, they were not tested in the 4-tube 
assay. Detection of Influenza A virus H1N1pdm09 was per-
formed by an in-house RT-PCR assay using primer set targeting 
HA (haemagglutinin) gene segment 4 (forward primer, 
5’-GTTACCCAGGAGATTTCATCGA-3’; reverse primer, 
5’-CATGCTGCCGTTACACCTTTG-3’; and probe, 5’-FAM-
AAGTTCATGGCCCAATCATGACTCGA-BHQ1-3’ [FAM, 
6-carboxyfluorescein, BHQ1, black hole quencher 1]). The 
reference was considered to be positive if any one of the refer-
ence assays was positive.
Data analysis and statistical analysis
Performance of the Luminex assay was evaluated as diagnostic 
yields and positive rate of pathogens detected by the Luminex 
compared to reference assays with 95% confidence interval 
using 2x2 tables. The calculation of these was performed with 
Intercooled Stata 9.2 (Stata, College station, TX, USA). Agreement 
between the Luminex and reference assays was determined by 
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Kappa statistic using SPSS version 23 (IBM Corp. SPSS Statistic, 
NY, USA). McNemar test (SPSS version 23) was used to examine 
whether there was any difference of diagnostic rates of individual 
viruses between the Luminex and reference assays. Statistical 
significance was set at P<0.05.
Results
Baseline results
A total of 442 samples collected between November 2012 and 
April 2014 were analysed for the evaluation of the Luminex assay. 
Three hundred forty-eight samples were from children (≥15 years 
old) and 94 samples from adults. The male/female ratio was 
0.62 (273): 0.38 (169). The median age of children was 1 year 
(Interquartile range, IQR: 1, 2) and of adults 46 years (IQR: 34, 
72). Overall, 302 specimens (68.3%) were positive by either 
Luminex or reference assays or both. One hundred forty 
samples (31.7%) remained undiagnosed. ENT/Rhi was the most 
frequently detected pathogen by the two techniques (159 over 
403 total count of all pathogens, 40%), followed by hBoV (n = 45, 
11%) and PIV3 (n = 42, 10%). Less frequently detected were 
ADV (n = 32, 8%), hMPV (n = 29, 7%), InFA (n = 22, 6%), 
hCoV (n = 22, 6%), RSV A and B (n = 21, 5%), PIV4 (n = 12, 3%), 
InFB (n = 10, 2.5%), PIV1 (n = 6, 1%) and PIV2 (n = 3, 0.5%).
Comparison of the Luminex xTAG RVP FAST v2 test and 
references
Diagnostic yields of Luminex and reference assays were 66.7% 
(295/442, 95% CI, 62.1-71.1%) and 54.1% (239/442, 95% CI, 
49.3-58.8%), respectively. The frequency of pathogens detected 
by Luminex and reference assays was 379 and 292, respectively. 
Shown in Figure 1 is number of cases that were positive for indi-
vidual viruses detected by the Luminex and reference assays. The 
Luminex assay had a higher detection rate for most viruses, but 
significant differences were seen in ENT/Rhi (99% versus 57%, 
P=0.001, McNemar test) and PIV4 (100% versus 42%, P=0.01, 
McNemar test). In contrast, for hBoV, RSV and InFB, the reference 
assays had higher detection rates (78% versus 96%, P=0.04; 90% 
versus 100%, P>0.05; and 90% versus 100%, P>0.05; respectively). 
Regarding mixed-infection, the Luminex assay also detected more 
co-infections compared to the reference assays: 68 versus 47. The 
maximum number of pathogens detected in a single patient was 
4. Parechoviruses were detected in four samples by the reference 
assays, but were not included in the Luminex assay. HCoV were 
not subtyped by reference assays.
Evaluation of the test performance and agreement 
between assays
Table 2 shows the diagnostic performance of the Luminex assay 
on clinical swabs against reference assays. Overall, 270 pathogens 
[91.8% (95% CI, 88.1-94.7)] detected by reference assays were 
also detected by Luminex assay (true positive rate or “sensitivity” 
against reference assays as gold standard). There were 112 
pathogens detected by Luminex but not detected by references, 
corresponding to a 1.8% (95%CI: 1.4-2.1) detection rate. In addi-
tion, there were 24 pathogens detected by reference assays but not 
detected by the Luminex, corresponding to 0.3% (95% CI: 0.2-0.6) 
detection rate.
For individual targets, positive detection by Luminex among 
references was more often for 13 targets, ranging from 88.8% to 
100% (ENT/Rhi, PIV3, ADV, hMPV, InFA matrix, H1N1pdm09, 
H3N2, hCoV, RSVA, PIV4, InFB, PIV1, PIV2), whilst it was less 
often positive for hBoV and RSVB (76.7% and 76.9%, respec-
tively). Remarkably, 43.4% (69/159) of ENT/Rhi were detected by 
Luminex but were negative by reference assays.
Among the 442 clinical swabs, concordance between the two tech-
niques was noted in 372 samples and discordance was recorded in 
Table 1. Primers and probe sequences of CDC influenza A/B virus PCR.
Primer name Oligo sequence (5'>3')
FluA Forward GACCRATCCTGTCACCTCTGAC
FluA Reverse AGGGCATTYTGGACAAAKCGTCTA
FluA probe FAM-TGCAGTCCTCGCTCACTGGGCACG-BHQ1
1977 seasonal H1 Forward AACTACTACTGGACTCTGCTGGAA
1977 seasonal H1 Reverse CCATTGGTGCATTTGAGGTGATG
1977 Seasonal H1 Probe1 FAM-TGAYCCAAAGCC”T” (BHQ1)CTACTCAGTGCGAAAGC
FluA H3 Forward AAGCATTCCYAATGACAAACC
FluA H3 Reverse ATTGCRCCRAATATGCCTCTAGT
FluA H3 Probe FAM-CAGGATCACATATGGGSCCTGTCCCAG-BHQ1
FluB Forward TCCTCAACTCACTCTTCGAGCG
FluB Reverse CGGTGCTCTTGACCAAATTGG
FluB probe FAM-CCAATTCGAGCAGCTGAAACTGCGGTG-BHQ1
Note: FAM: 6-carboxyfluorescein (FAM); BHQ1: Blackhole Quencher 1.
1: Taqman® probe is internally quenched at a modified “T” residue with BHQ1.
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Figure 1. Comparison of count of individual pathogens detected by the Luminex RVP FAST v2 and reference assays.
Table 2. Diagnostic performance of the Luminex RVP FAST v2 in comparison with reference assays.
Pathogens + L/+ ref + L/- ref -L/+ ref - L/-ref Positive rate by 
Luminex and ref 
(% [95% CI])
Positive rate by 
Luminex only 
(% [95% CI])
Kappa (95% CI)
ENT/Rhi 89 69 1 283 98.8 (93.9-99.9) 19.6 (15.6-24.1) 0.62 (0.54-0.69)
hBoV 33 2 10 397 76.7 (61.4-88.2) 0.5 (0.06-1.7) 0.83 (0.73-0.92)
PIV3 32 7 3 400 91.4 (76.9-98.2) 1.7 (0.6-3.5) 0.85 (0.77-0.92)
ADV 19 11 2 410 90.5 (69.6-98.8) 2.6 (1.3-4.6) 0.67 (0.53-0.80)
hMPV 20 8 1 413 95.2 (76.2-99.9) 1.9 (0.8-3.7) 0.80 (0.68-0.91)
InFA matrix* 3 0 0 439 100 (29.2-100) 0.0 (0.0-0.0) 1.00 (1.00-1.00)
H1N1pdm09 9 1 0 432 100 (66.4-100) 0.2 (0.0-1.2) 0.95 (0.85-1.05)
H3N2 10 0 0 432 100 (69.1-100) 0.0 (0.0-0.0) 1.00 (1.00-1.00)
hCoV (OC43, 
NL63, HKU1)
16 4 2 420 88.8 (65.3-98.6) 0.9 (0.2-2.3) 0.83 (0.71-0.94)
RSVA 9 0 1 432 100 (55.4-99.7) 0.0 (0.0-0.0) 0.95 (0.84-1.05)
RSVB 10 0 3 429 76.9 (46.2-94.9) 0.0 (0.0-0.0) 0.87 (0.73-1.00)
PIV4 5 7 0 430 100 (47.8-100) 1.6 (0.6-3.2) 0.58 (0.30-0.85)
InFB 9 0 1 432 90.0 (55.4-99.7) 0.0 (0.0-0.0) 0.94 (0.83-1.04)
PIV1 3 3 0 436 100 (29.2-100) 0.6 (0.1-1.9) 0.66 (0.30-1.01)
PIV2 3 0 0 439 100 (29.2-100) 0.0 (0.0-0.0) 1.00 (1.00-1.00)
Overall 270 112 24 6224 91.8 (88.1-94.7) 1.8 (1.4-2.1) 0.67 (0.61-0.73)
L: Luminex, ref: reference assays, * positive for M gene but negative for H1-1977, H1N1pdm09 and H3N2.
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70 samples, showing substantial agreement (overall kappa 0.67, 
95%CI 0.61–0.73). Table 2 also shows the test agreement of all 
viral pathogens. Almost perfect agreement was recorded in 10 
pathogens, hBoV, PIV3, InFA matrix, H1N1pdm09, H3N2, hCoV, 
RSVA, RSVB, InFB and PIV2 (kappa 0.83 – 1.00). Substantial 
agreement (kappa 0.62–0.80) was seen in hMPV, ENT/Rhi, ADV 
and PIV1, while agreement in PIV4 was moderate (kappa 0.58).
Evaluation of the Luminex xTAG Respiratory Viral Panel FAST 
v2 assay for detection of multiple respiratory viral pathogens in 
nasal and throat swabs in Vietnam
1 Data File 
Dataset 1: Respiratory Viral Diagnostic Result from 442 patient 
swabs of the Luminex and reference assays.
- Site: Abbreviation of provinces where hospitals involved in the 
study, where patients were recruited. (DlK: Daklak, DT: Dong Thap, 
H: Hue, and KH: Khanh Hoa)
- Gender: patient sex, 1: Male, 2: Female
- DateCollection: Date when patient samples were collected
- Flu A type (CDC): Results of influenza A and types from the 
reference assay: CDC Realtime RTPCR assay
- Flu B (CDC): Results of influenza B from the reference assay: CDC 
Realtime RTPCR assay
- RSV type: Results of RSV A and RSV B from in-house reference 
PCR assay
- detected by 4tube multiplexPCR: Results of other 10 viruses from 
reference assay: in-house 4-tube multiplex PCR
- Luminex result: Results from Luminex assay
- Diagnose: Final diagnosis based on Luminex and reference 
assays, it was defined “pos” if sample was positive with any of 
reference assays or Luminex assay, ”undiagnosed” if sample was 
negative with all reference assays and the Luminex assay
https://doi.org/10.6084/m9.figshare.5353630.v1 
Discussion
Fast and reliable diagnostic tests are a practical need in help-
ing physicians to make appropriate treatment decisions and are a 
useful tool in research and surveillance. We report here the 
evaluation of a Luminex assay on respiratory swabs collected 
from patients admitted to four provincial hospitals in Vietnam. 
Lacking a true “gold standard”, we combined a number of 
published PCR assays as reference tests for evaluation.
Overall positivity of Luminex among reference assays was high 
(91.8%, CI 95% 88.1–94.7). Ten viral targets had almost perfect 
agreement (kappa 0.81–1.00) between both assays. However, 
5 targets had lower agreement, in which 4 viral targets were at 
substantial agreement (0.61–0.80; hMPV, K=0.80, ENT/Rhi, 
K=0.62; PIV1, K=0.66; ADV, K=0.67) and one target was at only 
moderate agreement (PIV4, K=0.58). These 5 targets were all 
more often detected by Luminex (number of +L/-ref cases ranged 
from 3 – 69; Table 2) than by reference assays. This suggests that 
detection using Luminex is superior to reference assays for these 
targets.
Compared to reference assays, our study found an increased 
detection rate by the Luminex for most targets, and significant 
difference was seen in Ent/Rhi and PIV4 (+L/-ref= 69, p<0.001; 
and +L/-ref= 7, p=0.01, respectively; Figure 1). Especially a 
high number of +L/-ref for Ent/Rhi agent shows a considerable 
difference with other studies in previous xTAG Luminex 
studies15,18,23–25; it probably again reveals that Luminex is a strong 
assay in detection of this viral agent. Meanwhile, detection rate 
for hBoV was significantly higher in reference assays than in the 
Luminex (10 versus 2, p=0.04; Figure 1), which is similar to other 
previous studies15,18 (sensitivity of Luminex for this viral agent was 
rather low, 41.4% and 20.0% in these studies, respectively).
Though the Luminex assay may be of benefit to diagnostics and 
cost of treatment12,13,15,17,26, it requires a specific instrument for 
detection and data acquisition. Therefore, it may not be appro-
priate to laboratories with limited equipment. However, with a 
highly automated system and the capacity to test up to 94 
specimens within two hours (not including nucleic acid extrac-
tion and hands-on time), this high throughput Luminex RVP 
FAST method would be useful in large hospitals where they could 
have high input of respiratory samples to run by batch.
Globally, the fear of clinical worsening for patients with ARI 
usually results in empiric antibiotic prescription, even though 
doctors are aware that most ARI are caused by viruses. One of 
the factors contributing to this is the long interval between sam-
pling and reporting of test results. The Luminex assay may be part 
of the solution to this with its fast turnaround time.
The Luminex has a number of weaknesses: it cannot distinguish 
enterovirus and rhinovirus, it is not quantitative, it comprises a 
two-tube step for RT-PCR and DNA hybridization, including an 
open-tube step for transferring PCR product from RT-PCR tube to 
hybridization tube, which brings a risk for contamination, and it 
is expensive. A significantly lower positivity rate of the Luminex 
assay for hBoV found in this study (P=0.04) is also a weakness of 
this kit, which may need further clinical evaluation.
Limitations of this study are the lack of a true gold standard as 
is commonly seen when evaluating diagnostic assays and low 
numbers of positive samples for several ‘uncommon’ viruses 
(such as PIV1, PIV2). This low number of positive samples may 
conceal true diagnostic rates for these viruses.
In conclusion, our study shows the Luminex RVP FAST has a 
good diagnostic performance for detection of multiple respira-
tory viruses. Results from this study provided an additional eval-
uation on the utility of this commercial test. Though the cost of 
Luminex assay is rather high, Luminex RVP FAST platform could 
become affordable in large hospitals where samples are high 
input, reducing cost of the test by batch run. Once the per assay 
cost of this assay become more affordable, the above advantages 
and the short turnaround time could contribute to improving 
patient management and changing the prescription culture in 
countries like Vietnam.
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Data availability
Figshare: Evaluation of the Luminex xTAG Respiratory Viral Panel 
FAST v2 assay for detection of multiple respiratory viral pathogens 
in nasal and throat swabs in Vietnam
Dataset 1: Respiratory Viral Diagnostic Result from 442 patient 
swabs of the Luminex and reference assays.
https://doi.org/10.6084/m9.figshare.5353630.v127
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